Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018
Breast Cancer Research and Treatment · 2024
DOI: 10.1007/s10549-024-07453-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Erin J Aiello Bowles und 10 weiteren Autor:innen. Beteiligte Einrichtung: Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, 1730 Minor Ave, Suite 1360, Seattle, WA, 98101, USA. erin.a.bow…. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Antineoplastic Agents, Hormonal, Tamoxifen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, RTI International, US National Cancer Institute.
Abstract (Originalsprache)
PURPOSE: Trials demonstrating benefits of tamoxifen for women with ductal carcinoma in situ (DCIS) were published > 20 years ago; yet subsequent uptake of endocrine therapy was low. We estimated endocrine therapy initiation in women with DCIS between 2001 and 2018 in a community setting, reflecting more recent years of diagnosis than previous studies. METHODS: This retrospective cohort included adult females ≥ 20 years diagnosed with first primary DCIS between 2001 and 2018, followed through 2019, and enrolled in one of three U.S. integrated healthcare systems. We collected data on endocrine therapy dispensings (tamoxifen, aromatase inhibitors [AIs]) from electronic pharmacy records within 12 months after DCIS diagnosis. Using generalized linear models with a log link and Poisson distribution, we estimated endocrine therapy initiation rates over time and by patient, tumor (including estrogen receptor [ER] status), and treatment characteristics. RESULTS: Among 2020 women with DCIS, 587 (29%) initiated endocrine therapy within 12 months after diagnosis (36% among 1208 women with ER-positive DCIS). Among women who used endocrine therapy, 506 (86%) initiated tamoxifen and 81 (14%) initiated AIs. Age-adjusted endocrine therapy initiation declined from 34 to 21% between 2001 and 2017; between 2015 and 2018, AI use increased from 8 to 35%. Women less likely to initiate endocrine therapy were ER-negative or had borderline/unknown or no ER test results, ≥ 65 years at diagnosis, Black, and received no radiotherapy. CONCLUSION: One-third of women diagnosed with DCIS initiated endocrine therapy, and use decreased over time. Understanding why women eligible for endocrine therapy do not initiate is important to maximizing disease-free survival following DCIS diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, 1730 Minor Ave, Suite 1360, Seattle, WA, 98101, USA. erin.a.bowles@kp.org.
- Cedars-Sinai Medical Center, Los Angeles, CA, USA.
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
- Bernard J. Tyson Kaiser Permanente School of Medicine, Pasadena, CA, USA.
- Institute for Health Research, Kaiser Permanente Colorado, Denver, CO, USA.
- Center for Research and Evaluation, Kaiser Permanente Georgia, Atlanta, GA, USA.
Förderung
- NCI NIH HHS
- RTI International
- US National Cancer Institute
- Division of Cancer Epidemiology and Genetics
Zitieren
APA
Bowles, E. J. A., Ramin, C., Vo, J. B., Feigelson, H. S., Gander, J. C., Veiga, L. H. S., Bodelon, C., Curtis, R. E., Brandt, C., Berrington de Gonzalez, A., & Gierach, G. L. (2024). Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07453-0
Vancouver
Bowles EJA, Ramin C, Vo JB, Feigelson HS, Gander JC, Veiga LHS, et al. Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07453-0
BibTeX
@article{Bowles2024,
author = {Bowles, Erin J Aiello and Ramin, Cody and Vo, Jacqueline B and Feigelson, Heather Spencer and Gander, Jennifer C and Veiga, Lene H S and Bodelon, Clara and Curtis, Rochelle E and Brandt, Carolyn and Berrington de Gonzalez, Amy and Gierach, Gretchen L},
title = {Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018},
journal = {Breast Cancer Research and Treatment},
year = {2024},
doi = {10.1007/s10549-024-07453-0}
}
EUVIMED